Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Compassionate Use Study of Tenalisib in Hematological Malignancies
2020-001663-90Phase 2Terminated
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hematopoietic malignancies, sponsored by Rhizen Pharmaceuticals AG. Started Jun 2020; status: terminated.
02
Drugs
tenalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)hematopoietic malignancies
Beyond the preview
Go deeper on 2020-001663-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001663-90.